Biorem Reports 2023 Financial Results including $0.14 earnings per share
FINANCIAL HIGHLIGHTS:
In '000's except earnings per share |
|||||
|
|
Thee-months ended |
Twelve-months ended |
||
|
|
|
|
||
|
|
2023 |
2022 |
2023 |
2022 |
|
|
|
|
|
|
|
|
|
|
|
|
Revenue |
12,207 |
10,911 |
25,165 |
28,863 |
|
Gross profit |
4,407 |
4,853 |
7,022 |
8,762 |
|
Operating Expenses |
1,329 |
2,594 |
3,959 |
6,121 |
|
Ebitda* |
3,270 |
1,342 |
3,441 |
2,775 |
|
Net earnings |
2,364 |
789 |
2,179 |
1,613 |
|
EPS - basic |
0.15 |
0.05 |
0.14 |
0.10 |
|
EPS - fully diluted |
0.14 |
0.05 |
0.13 |
0.09 |
|
*Earnings before interest, taxes and amortization, a non IFRS financial measure |
For the twelve months ended
Gross profit for the year was
Total operating expenses for the year were
On
Total order bookings for the year were
"Management looks forward to beginning the next phase of the Corporation's development", said
"We are particularly excited about expanding both our organic as well as inorganic growth initiatives. The market has been responsive to our new introductions and we expect the same level of interest with the next offering of complimentary technologies. A number of new initiatives are underway with results expected to begin to be realized within the coming quarters. All in all, a very exciting period for our company."
Revenue in the fourth quarter of 2023 was
Gross profit of
Total operating expenses (net of other income) for the quarter were
Ebitda for the quarter was
Net earnings for the quarter were
SOURCE